Intralesional Injection of Hyaluronic Acid in Patients Affected With Peyronie's Disease: Preliminary Results From a Prospective, Multicenter, Pilot Study

Overview

Journal Sex Med

Publisher Oxford University Press

Date 2016 Mar 18

PMID 26984291

Citations 20

Authors

Alessandro Zucchi

Elisabetta Costantini

Tommaso Cai

Giorgio Cavallini

Giovanni Liguori

Vincenzo Favilla

Gaetano De Grande

Giuseppe Dachille

Mauro Silvani

Giorgio Franco

Alessandro Palmieri

Paolo Verze

Vincenzo Mirone

Affiliations

Soon will be listed here.

Abstract

Introduction: Hyaluronic acid has been shown to be efficacious in decreasing scar formation, inflammation, and oxidative stress.

Aim: To assess the efficacy of intralesional injection of hyaluronic acid in patients affected by Peyronie's disease.

Methods: In this prospective, single-arm, self-controlled, interventional, multicenter pilot study, 65 patients underwent a 10-week cycle of weekly intraplaque injections with hyaluronic acid (0.8% highly purified sodium salt hyaluronic acid 16 mg/2 mL; Sinovial, IBSA, Lodi, Italy). Patients were re-evaluated 2 months after the end of therapy.

Main Outcome Measures: Plaque size (millimeters), penile curvature (degrees), International Index of Erectile Function (IIEF-5) score, visual analog scale (VAS) score for sexual satisfaction, and Patient's Global Impressions of Improvement (PGI-I) score.

Results: Median age was 57 years (range = 23-70). At baseline, mean plaque size was 10 mm (range = 3-30 mm), mean penile curvature was 30° (range = 0°-50°), and mean IIEF-5 score was 20 (range = 0-25), with slight to moderate erectile dysfunction (IIEF score < 21) in 36 of 65 patients (55%). A median VAS score of 6 (range = 2-10) was found. Mean follow-up was 12 months (range = 6-24 months). Statistically significant post-treatment improvements were detected for plaque size (before treatment = 10 mm [3-30 mm], after treatment = 8 mm [1-30 mm], P < .0001), penile curvature (before treatment = 30° [0°-50°], after treatment = 20° [0°-40°], P < .0001), IIEF-5 score (before treatment = 20 [11-25], after treatment = 21 [15-25], P < .0001), and VAS score (before treatment = 6 [2-10], after treatment 8 [2-10], P < .0001). After treatment, the rate of patients with an IIEF score lower than 21 decreased from 55% (36 patients) to 40% (25 patients). Overall improvement on the PGI-I questionnaire was 69%.

Conclusion: Intralesional treatment with hyaluronic acid can improve plaque size, penile curvature, and overall sexual satisfaction and seems preferably indicated in the early (active) phase of the disease. Furthermore, it is easy to perform and well tolerated.

Citing Articles

Oxidative Mechanism of Peyronie's Disease and Effectiveness of Pentoxifylline in the Therapeutic Management: A Narrative Review.

Paulis G, Paulis A Antioxidants (Basel). 2025; 14(2).

PMID: 40002394 PMC: 11851550. DOI: 10.3390/antiox14020208.

Intralesional injection of hyaluronic acid compared with verapamil in acute phase of Peyronie's disease: A prospective randomized clinical trial.

Abdel Fattah A, Diab T, El-Dakhakhny A, El Hamshary S Arab J Urol. 2024; 22(4):206-211.

PMID: 39355797 PMC: 11441066. DOI: 10.1080/20905998.2024.2333583.

Acute Phase Peyronie's Disease: Where Do We Stand?.

Douroumis K, Kotrotsios K, Katsikatsos P, Moulavasilis N, Fragkiadis E, Mitropoulos D Cureus. 2024; 16(8):e67054.

PMID: 39286663 PMC: 11403542. DOI: 10.7759/cureus.67054.

Measurement of Oxidative Stress Index (OSI) in Penile Corpora Cavernosa and Peripheral Blood of Peyronie's Disease Patients: A Report of 49 Cases.

Paulis G, Paulis A, De Giorgio G, Quattrocchi S Metabolites. 2024; 14(1).

PMID: 38248858 PMC: 10821449. DOI: 10.3390/metabo14010055.

The role of surgical therapy in the management of premature ejaculation: a narrative review.

Ambusaidi H, Alshuaibi M, Zugail A, Beley S Transl Androl Urol. 2023; 12(10):1589-1597.

PMID: 37969778 PMC: 10643386. DOI: 10.21037/tau-23-240.

References

Gelbard M, Goldstein I, Hellstrom W, McMahon C, Smith T, Tursi J . Clinical efficacy, safety and tolerability of collagenase clostridium histolyticum for the treatment of peyronie disease in 2 large double-blind, randomized, placebo controlled phase 3 studies. J Urol. 2013; 190(1):199-207. DOI: 10.1016/j.juro.2013.01.087. View

Soh J, Kawauchi A, Kanemitsu N, Naya Y, Ochiai A, Naitoh Y . Nicardipine vs. saline injection as treatment for Peyronie's disease: a prospective, randomized, single-blind trial. J Sex Med. 2010; 7(11):3743-9. DOI: 10.1111/j.1743-6109.2010.01924.x. View

Chen C, Hsu C, Pei Y, Chen R, Zhou S, Shen H . Changes of synovial fluid protein concentrations in supra-patellar bursitis patients after the injection of different molecular weights of hyaluronic acid. Exp Gerontol. 2014; 52:30-5. DOI: 10.1016/j.exger.2014.01.016. View

Gonzalez-Cadavid N, Rajfer J . Mechanisms of Disease: new insights into the cellular and molecular pathology of Peyronie's disease. Nat Clin Pract Urol. 2006; 2(6):291-7. DOI: 10.1038/ncpuro0201. View

Nelson C, Diblasio C, Kendirci M, Hellstrom W, Guhring P, Mulhall J . The chronology of depression and distress in men with Peyronie's disease. J Sex Med. 2008; 5(8):1985-90. DOI: 10.1111/j.1743-6109.2008.00895.x. View

Asada S, Fukuda K, Oh M, Hamanishi C, Tanaka S . Effect of hydrogen peroxide on the metabolism of articular chondrocytes. Inflamm Res. 1999; 48(7):399-403. DOI: 10.1007/s000110050478. View

Cipollone G, Nicolai M, Mastroprimiano G, Iantorno R, Longeri D, Tenaglia R . [Betamethasone versus placebo in Peyronie's disease]. Arch Ital Urol Androl. 1998; 70(4):165-8. View

Brock G, Hsu G, Nunes L, von Heyden B, Lue T . The anatomy of the tunica albuginea in the normal penis and Peyronie's disease. J Urol. 1997; 157(1):276-81. View

Mulhall J, Creech S, Boorjian S, Ghaly S, Kim E, Moty A . Subjective and objective analysis of the prevalence of Peyronie's disease in a population of men presenting for prostate cancer screening. J Urol. 2004; 171(6 Pt 1):2350-3. DOI: 10.1097/01.ju.0000127744.18878.f1. View

10.

El-Sakka A, Hassoba H, Chui R, Bhatnagar R, Dahiya R, Lue T . An animal model of Peyronie's-like condition associated with an increase of transforming growth factor beta mRNA and protein expression. J Urol. 1997; 158(6):2284-90. DOI: 10.1016/s0022-5347(01)68236-3. View

11.

Musitelli S, Bossi M, Jallous H . A brief historical survey of "Peyronie's disease". J Sex Med. 2008; 5(7):1737-46. DOI: 10.1111/j.1743-6109.2007.00692.x. View

12.

Van de Water L . Mechanisms by which fibrin and fibronectin appear in healing wounds: implications for Peyronie's disease. J Urol. 1997; 157(1):306-10. DOI: 10.1097/00005392-199701000-00103. View

13.

Gonzalez-Cadavid N, Magee T, Ferrini M, Qian A, Vernet D, Rajfer J . Gene expression in Peyronie's disease. Int J Impot Res. 2002; 14(5):361-74. DOI: 10.1038/sj.ijir.3900873. View

14.

Hellstrom W, Kendirci M, Matern R, Cockerham Y, Myers L, Sikka S . Single-blind, multicenter, placebo controlled, parallel study to assess the safety and efficacy of intralesional interferon alpha-2B for minimally invasive treatment for Peyronie's disease. J Urol. 2006; 176(1):394-8. DOI: 10.1016/S0022-5347(06)00517-9. View

15.

Shirazi M, Haghpanah A, Badiee M, Afrasiabi M, Haghpanah S . Effect of intralesional verapamil for treatment of Peyronie's disease: a randomized single-blind, placebo-controlled study. Int Urol Nephrol. 2009; 41(3):467-71. DOI: 10.1007/s11255-009-9522-4. View

16.

Hatzimouratidis K, Eardley I, Giuliano F, Hatzichristou D, Moncada I, Salonia A . EAU guidelines on penile curvature. Eur Urol. 2012; 62(3):543-52. DOI: 10.1016/j.eururo.2012.05.040. View

17.

Schwarzer U, Sommer F, Klotz T, Braun M, Reifenrath B, Engelmann U . The prevalence of Peyronie's disease: results of a large survey. BJU Int. 2002; 88(7):727-30. DOI: 10.1046/j.1464-4096.2001.02436.x. View

18.

Berookhim B, Choi J, Alex B, Mulhall J . Deformity stabilization and improvement in men with untreated Peyronie's disease. BJU Int. 2013; 113(1):133-6. DOI: 10.1111/bju.12346. View

19.

Viktrup L, Hayes R, Wang P, Shen W . Construct validation of patient global impression of severity (PGI-S) and improvement (PGI-I) questionnaires in the treatment of men with lower urinary tract symptoms secondary to benign prostatic hyperplasia. BMC Urol. 2012; 12:30. PMC: 3503561. DOI: 10.1186/1471-2490-12-30. View

20.

Yu C, Ko C, Hsieh C, Chien C, Huang L, Lee C . Proteomic analysis of osteoarthritic chondrocyte reveals the hyaluronic acid-regulated proteins involved in chondroprotective effect under oxidative stress. J Proteomics. 2014; 99:40-53. DOI: 10.1016/j.jprot.2014.01.016. View